Coldman AJ, van Niekerk D, Krajden M, et al. - Researchers describe the findings of a randomized control trial of cervical cancer screening, named HPV FOCAL. This trial was done with an intervention arm and a control arm. Baseline screening for high-risk human papillomavirus (HPV) was provided in the intervention arm, and liquid-based cytology (LBC) at baseline and 24 months was received by the control arm. In this trial, 48-month exit HPV and LBC cotesting were received by both arms. For per-protocol eligible (PPE) screened women, exit outcomes were presented. It was noted that exit cotest outcomes were similar by arm for PPE, and for intervention vs control, the relative rate of CIN2+ (cervical intraepithelial neoplasia Grade 2 or worse) was 0.83. In this per-protocol study, screening with HPV using a 4-year interval and LBC with a 2-year screening interval, both were found equally safe. Few additional lesions were found via LBC screening in HPV negative women at exit.